載入中
NASDAQHealthcareBiotechnology
最新資料
US$52.90
−US$1.64 · -3.01%
MBX Biosciences, Inc. is a biopharmaceutical company in its clinical development phase, dedicated to pioneering precise peptide-based therapies for endocrine and metabolic conditions. Its most advanced drug candidate, MBX 2109, is a parathyroid hormone peptide prodrug currently in Phase 2 clinical trials. This medication is being evaluated as a long-duration hormone replacement treatment for individuals suffering from chronic hypoparathyroidism. The company is also progressing with MBX 1416, a prolonged-action glucagon-like peptide-1 (GLP-1) receptor antagonist, which is undergoing Phase 1 clinical assessment. The aim of this therapy is to address post-bariatric hypoglycemia, a persistent complication often seen after weight-loss surgery. Furthermore, MBX Biosciences is developing MBX 4291, a key candidate for obesity treatment. This highly potent and long-acting prodrug functions as a co-agonist for both GLP-1 and glucose-dependent insulinotropic polypeptide (GIP) receptors. It is currently in investigational new drug (IND)-enabling studies, with the intention of treating obesity and its associated health issues. Founded in 2018, the company's operations are headquartered in Carmel, Indiana.
一般交易時段
US$52.90
−US$1.64 · -3.01%
盤中時間採用ET。市場資料可能有所延遲。
MBX Biosciences, Inc. is a biopharmaceutical company in its clinical development phase, dedicated to pioneering precise peptide-based therapies for endocrine and metabolic conditions. Its most advanced drug candidate, MBX 2109, is a parathyroid hormone peptide prodrug currently in Phase 2 clinical trials. This medication is being evaluated as a long-duration hormone replacement treatment for individuals suffering from chronic hypoparathyroidism. The company is also progressing with MBX 1416, a prolonged-action glucagon-like peptide-1 (GLP-1) receptor antagonist, which is undergoing Phase 1 clinical assessment. The aim of this therapy is to address post-bariatric hypoglycemia, a persistent complication often seen after weight-loss surgery. Furthermore, MBX Biosciences is developing MBX 4291, a key candidate for obesity treatment. This highly potent and long-acting prodrug functions as a co-agonist for both GLP-1 and glucose-dependent insulinotropic polypeptide (GIP) receptors. It is currently in investigational new drug (IND)-enabling studies, with the intention of treating obesity and its associated health issues. Founded in 2018, the company's operations are headquartered in Carmel, Indiana.
日內區間
目前US$52.90
52週區間
目前US$52.90
盤中時間採用ET。市場資料可能有所延遲。
MBX Biosciences, Inc. is a biopharmaceutical company in its clinical development phase, dedicated to pioneering precise peptide-based therapies for endocrine and metabolic conditions. Its most advanced drug candidate, MBX 2109, is a parathyroid hormone peptide prodrug currently in Phase 2 clinical trials. This medication is being evaluated as a long-duration hormone replacement treatment for individuals suffering from chronic hypoparathyroidism. The company is also progressing with MBX 1416, a prolonged-action glucagon-like peptide-1 (GLP-1) receptor antagonist, which is undergoing Phase 1 clinical assessment. The aim of this therapy is to address post-bariatric hypoglycemia, a persistent complication often seen after weight-loss surgery. Furthermore, MBX Biosciences is developing MBX 4291, a key candidate for obesity treatment. This highly potent and long-acting prodrug functions as a co-agonist for both GLP-1 and glucose-dependent insulinotropic polypeptide (GIP) receptors. It is currently in investigational new drug (IND)-enabling studies, with the intention of treating obesity and its associated health issues. Founded in 2018, the company's operations are headquartered in Carmel, Indiana.
日內區間
目前US$52.90
52週區間
目前US$52.90
營業利益
淨利
| 項目（USD） | 2025會計年度 | 2024會計年度 | 2023會計年度 | 2022會計年度 |
|---|---|---|---|---|
| 銷貨成本 | 24.8萬 USD | — | — | — |
| 毛利 | −24.8萬 USD | — | — | — |
| 研究與開發 | 7915.9萬 USD | 5741.5萬 USD | 2853.4萬 USD | 2139.7萬 USD |
| 銷售、一般及管理費用 | 1889.6萬 USD | 1077.9萬 USD | 677.7萬 USD | 376.4萬 USD |
| 營業費用 | 9805.5萬 USD | 6819.4萬 USD | 3531.1萬 USD | 2516.1萬 USD |
| 利息收入 | 1108.4萬 USD | 627.2萬 USD | 274.8萬 USD | 37.2萬 USD |
| 利息支出 | — | — | — | 37.4萬 USD |
| 折舊和攤銷 | 24.8萬 USD | 24.4萬 USD | 15.7萬 USD | 5.6萬 USD |
| 營業利益 | −9805.5萬 USD | −6819.4萬 USD | −3531.1萬 USD | −2516.1萬 USD |
| 淨利 | −8697.1萬 USD | −6192.2萬 USD | −3256.3萬 USD | −2613.5萬 USD |
公司資料更新於 2026年10月8日。
近期已公布業績
報告持有此股票曝險的交易所交易基金。
Vanguard Morningstar Total Stock Market ETFVTI7011.74萬0.00%2.3兆 USD0.03%US$380.28-0.20%
iShares Russell 2000 ETFIWM4455.98萬0.06%785.63億 USD0.19%US$276.25-0.52%
Vanguard Extended Market ETFVXF1903.69萬0.02%954億 USD0.05%US$232.56-0.40%
iShares Russell 2000 Growth ETFIWO1584.77萬0.11%142.49億 USD0.24%US$352.4-0.84%
iShares Biotechnology ETFIBB1258.59萬0.12%104.01億 USD0.44%US$198.11-2.57%
Vanguard Russell 2000 ETFVTWO1099.18萬0.06%180億 USD0.06%US$111.57-0.57%
State Street SPDR S&P Pharmaceuticals ETFXPH906.83萬1.86%4.62億 USD0.35%US$62.79-0.19%
Schwab U.S. Small-Cap ETFSCHA884.02萬0.04%216.99億 USD0.03%US$32.48-0.40%Vanguard Morningstar Total Stock Market ETFVTIiShares Russell 2000 ETFIWMVanguard Extended Market ETFVXFiShares Russell 2000 Growth ETFIWOiShares Biotechnology ETFIBBVanguard Russell 2000 ETFVTWOState Street SPDR S&P Pharmaceuticals ETFXPHSchwab U.S. Small-Cap ETFSCHAAI 生成內容及延遲市場資料僅供資訊與教育用途，不構成投資建議。
